Effect of nifedipine combined with magnesium sulfate on gestational hypertension and its impact on blood lipids

Objective This study aimed to evaluate the efficacy of nifedipine combined with magnesium sulfate in pregnant women with gestational hypertension (GH) and its influence on blood lipid levels. Methods Seventy pregnant women with GH were randomly assigned to either a control group (labetalol plus magnesium sulfate) or an observation group (nifedipine extended-release tablets plus magnesium sulfate) ( n = 35). Both groups were treated for 7 days. Posttreatment, changes in blood pressure (SBP and DBP), hemorheological parameters [whole blood high-shear viscosity, low-shear viscosity, plasma viscosity (PV)], blood lipid levels [high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and total cholesterol (TC)], adverse reactions, and pregnancy outcomes were assessed. Results Posttreatment, both groups showed significant reductions in SBP and DBP, with greater decreases in the observation group ( P < 0.05). After 7 days of treatment, whole blood high-shear viscosity, low-shear viscosity, and PV decreased in both groups, with lower values for these in the observation group ( P < 0.05). Lipid profiles improved in both groups, with the observation group showing higher HDL-C and lower LDL-C, TG, and TC ( P < 0.05). The observation group had a higher overall efficacy rate (94.29 vs. 77.14%, P < 0.05) and fewer adverse pregnancy outcomes (8.57% vs. 28.57%, P < 0.05), while the incidence of adverse reactions was comparable between groups. Conclusion Nifedipine combined with magnesium sulfate is more effective in managing GH. This regimen better improves blood pressure, hemorheological parameters, lipid profiles, and pregnancy outcomes, with good safety.